Emerging Companies

Lenz: focused on an eye drop for age-related farsightedness

Lenz is well-financed to begin a pivotal study of a pupil-contracting eye drop addressing the largest market in ophthalmology: presbyopia, or age-related farsightedness. Backed by Versant Ventures and RA Capital, newly rechristened Lenz Therapeutics Inc. will...

Mnemo: advancing next-generation cell therapies against epigenetic antigens

Mnemo has raised the largest ever series A round for a French biotech to develop a next-generation CAR T platform and bring its cell therapies into a new target space against epigenetic antigens. Founding investor...

VectorY: Forbion’s next-generation gene therapy play

Forbion-backed VectorY is assembling a set of tools and key personnel to create vectorized antibody therapeutics designed to fill a gap in diseases where other mAbs and gene therapies have fallen short, beginning with ALS. Rather...

Scenic: targeting genetic modifiers to suppress disease drivers

Scenic Biotech is building a compendium of genetic data to identify rare, naturally occurring genetic modifiers that suppress disease pathology despite the presence of disease-causing mutations. Many rare...

Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers

With an initial focus on MYC-driven cancers, Anticancer Bioscience joins a growing wave of next-generation synthetic lethality companies looking beyond the DNA damage response pathway kinases that have dominated the space. President and CEO Dun...

Kojin launches to exploit ferroptosis-vulnerable cancer cell state

Kojin, which launched Wednesday with a $60 million series A led by Polaris Partners, Newpath Partners and Cathay Health, is pursuing drug development with an approach based on cell state biology,...

With Medicxi’s backing, Kurome seeks best-in-class IRAK4 program for blood cancers

With early clinical data emerging that suggest a combination of IRAK4 and FLT3 inhibition may be effective in treating acute myelogenous leukemia, Medicxi has thrown its weight behind Kurome, a spinout...

Stablix takes targeted protein degradation’s tactics in reverse

Stablix is the among the first companies founded to extend the logic of protein degradation to a different enzymatic process — in this case, stabilizing proteins via deubiquitination. The company emerged...

Interius design: Penn spinout gets specific with in vivo CAR Ts

Cell and gene therapy company Interius has $76 million from a series A funding led by Bihua Chen’s Cormorant and Fairmount and the guidance of Executive Chairman Lonnie Moulder to develop an in vivo...

EpyGenix: Fishing for best in class in epilepsy

EpyGenix has leveraged its animal model of Dravet syndrome to identify three repurposed molecules that have shown high levels of preclinical efficacy. The biotech is hoping the well-established safety...

Variant Bio: creating a new social contract for genome-based drug discovery

Variant Bio aims to develop drugs based on data gathered in collaboration with groups that have maintained genetic and often cultural distance from the populations that dominate genomic databases. The...

Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies

Outpace is taking cell and gene control technology originally in-licensed by Lyell out of that company’s toolbox and into a broad partnering model it thinks could transform the field.  Outpace Bio Inc. launched in March...

Allero: treating food-related immune diseases through an oral patch

Allero emerged from stealth last year to develop an oral patch-based immunotherapy that could lead to better compliance and fewer safety risks than other treatments in the expanding food allergy and Celiac...

Wugen: deploying memory NK cells against cancer

Wugen is adding a new subset of NK cells to the cell therapy toolkit with its memory NK cell approach, which may lead to high antitumor efficacy without requiring a CAR or other modifications. ...

Median seed, A round sizes have more than doubled since 2017

With less than half a year in the books, it’s clear that the 2021 crop of newcos is accelerating the trend of the past few years in drawing bigger rounds from investors to get...